Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Upendra Singh, Commercial Head - General Medicines, effective from the close of business hours of 18th April 2025.

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.

SEONGNAM, South Korea I April 7, 2025 I ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier. GSK is fronting £38.5 million (nearly $50 million), in a partnership with ...

Speaking about the book, Ebbi said: “Inspired by a senior executive from Glaxo SmithKline, who attended our Best Foot Programme in Sheraton, I have written “My Little Book of Etiquette.” “This ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

FTSE 100 pharmaceutical giants GSK and Astrazeneca may have avoided the brunt of US President Donald Trump's tariffs, a City broker suggests. Pharmaceutical goods seem to be exempt from the ...